Tracy Johnson, Ph.D. – Keynote speaker, 2021 RNA Symposium



KEYNOTE SPEAKER 1: March 25, 2021, 11:05–12:00 pm

More information on the Symposium

Blog by MiSciWriters

“RNA Splicing, Chromatin Modification, and the Coordinated Control of Gene expression”
Tracy Johnson, Ph.D., University of California – Los Angeles

Keith and Cecilia Terasaki Endowed Chair in the Life Sciences
Professor of Molecular, Cell and Developmental Biology
Howard Hughes Medical Institute Professor
Dean, Division of Life Sciences
University of California – Los Angeles

The Tracy Johnson Lab
Twitter: @TheTracyLab

 

TALK ABSTRACT
Pre-messenger RNA splicing is carried out by the spliceosome, a dynamic ribonucleoprotein complex that is functionally conserved across eukaryotes.  The spliceosome assembles onto pre-mRNA co-transcriptionally, raising important questions about how the process of transcription through a chromatin template influences spliceosome assembly and splicing outcomes. Furthermore, the close spatial and physical proximity of the splicing and transcription machineries raises the possibility of bi-directional regulation of these processes.  Finally, regulation of spliceosome assembly and the fate of both spliced and unspliced RNAs provides an elegant mechanism for controlling gene expression. Understanding how these mechanisms are regulated in response to changes in the cell’s environment remains an important and exciting challenge. Here I will describe our recent insights into these questions.

REFERENCES
Leung, C., Douglass, S., Morselli, M., Obusan, M.B. Pavlyukov, M.S., Pelligrini, M., and T.L. Johnson. 2019. H3K36 methylation and the chromodomain-protein Eaf3 are required for proper co-transcriptional splicing. Cell Reports, 27(13):3760-3769.e4. PMID:31242410

Hossain, M.A.*, Claggett, J.C.* (*Co-first authors), Edwards, S.E., Shi, A., Pennebaker, S., Cheng, M. Hasty, J. and T.L. Johnson. 2016. Post-transcriptional regulation of Gcr1 expression and activity are crucial for metabolic adjustment in response to glucose availability. Molecular Cell 62:346-358. PMID: 27153533. PMCID: PMC5117908

 

Similar Posts

  • Giving Blueday 2026 is here!

    Support what you 💛 about the Center for RNA Biomedicine! CENTER FOR RNA BIOMEDICINE – GIFT ACCOUNT – 330716 At the University of Michigan, the Center for RNA Biomedicine stands at the forefront of scientific discovery, transforming how we understand and treat diseases at the genetic level. Our mission is simple yet profound: to harness…

  • Feng Zhang, Ph.D. – Keynote speaker, 2021 RNA Symposium

    KEYNOTE SPEAKER 3: March 25, 2021, 1:35–2:30 pm More information on the Symposium Blog by MiSciWriters “Exploration of Biological Diversity to Discover Novel Molecular Technologies” Feng Zhang, Ph.D. James and Patricia Poitras Professor of Neuroscience at MIT, Howard Hughes Medical Institute Investigator, Professor, Brain and Cognitive Sciences and Biological Engineering at MIT Core Member, Broad…

  • |

    Repurposing Prostate Cancer Drug for COVID-19

    In our September 2020 issue of RNA Translated, 2020 the year of the RNA virus, we presented how University of Michigan (U-M) Center for RNA Biomedicine’s scientists pivoted their research to address the COVID-19 pandemic. One of them is Dr. Chinnaiyan and his team of prostate cancer researchers who focused on two proteins that are…

  • RNA Translated 2024 is out in wide release!

    The latest issue of RNA Translated, the University of Michigan Center for RNA Biomedicine annual magazine and brief report, has been published and is available in print and to view online now!   The 2024 issue focuses on our groundbreaking efforts to build a University of Michigan “M-RNA Therapeutics” initiative, led by Michelle Hastings, Ph.D.,…

  • After COVID-19, mRNA vaccines could treat flu, HIV and even cancer

    By Justin P. Hicks | jhicks3@mlive.com Vaccines to protect against severe illness and death from COVID-19 started as the key to a return to normal, but they could wind up unlocking much more for the future of health care. The mRNA vaccine technology used by Pfizer/BioNTech and Moderna for their respective coronavirus vaccines has been heavily…